GSK’s Tanzeum Launch Marks The Big Pharma’s Return To Diabetes
This article was originally published in The Pink Sheet Daily
GSK expects Tanzeum will be one of its “core big six” drugs despite the fact that it is the fourth GLP-1 to market. VP-General Medicines Cheryl MacDiarmid discussed GSK’s return to diabetes in an interview.
You may also be interested in...
The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.
GSK returned US rights to the IL-6 blocker to J&J as it prioritizes its pharma portfolio under the leadership of new CEO Walmsley.
As the era of the primary care blockbusters waned, pharma R&D shifted toward less price-sensitive specialty fields. Now successful specialty drug development is producing its own sort of follow-on agents, and payers are pushing back. Even oncology is not immune.